The Intelligent Positive Air Pressure Machine
The COVID-19 crisis has dramatically changed the realities of our world today.
Even as countries like the US and India are scrambling to innovate workarounds for critical medical devices and ramp up production capacity, there is a significant gap in meeting the needs of the developing world. In these contexts, patients only have access to primary health clinics where resources and skilled health workers are in short supply.
Delays in mobilizing resources for these regions could result in devastating consequences for the global impact of COVID-19.
Among the key device innovations needed to begin addressing this gap are low-cost breathing-assist devices.
Most innovations are targeted towards patients who are in advanced stages of the COVID-19 disease progression. Between existing devices and these recent innovations, there is still a major gap in the types of devices needed, particularly for patients needing assistance in the earlier stages of the COVID-19 progression. ITT and its partners are developing a simple, affordable device to target a gap in the current breathing solutions.
The Intelligent Positive Air Pressure (iPAP) machine is an integrated device that includes these functionalities for $500 per base model. It is an ideal device to address Stage Four COVID patients.
This low-cost intervention will address the needs of the vast majority of patients that will be infected with COVID-19 in developing countries and are able to be administered by a nurse or a community health worker, making it an ideal technology to be deployed in primary health care centers.
We are working to bring this product to market and scale in emerging countries. The initiative is supported by an advisory panel consisting of renowned experts in public health and COVID-19 response, practicing clinicians from target countries, as well as medical device companies at the forefront of the global response.